Larvol Delta - New-Phase-1-Dose-Escalation-Data-Show-WellTolerated-Safety-Prole-and-AntiTumor-Activity-for-Aulos-Biosciences-AU007-at-Society-for-Immunotherapy-of-Cancer-SITC-Annual-Meeting

AU-007 - Aulos Biosci

https://www.businesswire.com/news/home/20231103536244/en/New-Phase-1-Dose-Escalation-Data-Show-Well-Tolerated-Safety-Profile-and-Anti-Tumor-Activity-for-Aulos-Bioscience%E2%80%99s-AU-007-at-Society-for-Immunotherapy-of-Cancer-SITC-Annual-Meeting

Nov 3, 2023

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next